生物製劑先導工廠製程空間建築規劃之研究

A Study of Architectural Planning on Production Space of Biologic Pharmaceutical Pilot Factory

10.6377/JA.201106.0002

喻文莉(Wen-Li Yu)；郭斯傑(Sy-Jye Guo)

生物製劑先導工廠 ； 製程空間 ； 生物安全第三等級實驗室 ； 藥品優良製造確效作業基準 ； Biological Pharmaceutical Pilot Factory ； Production Space ； Biosafety Level 3 Laboratory BSL3 ； GMP Good Manufacturing Practice Job Baseline

建築學報

76期（2011 / 06 / 28）

23 - 42

繁體中文

本研究以屬高危險性質之「生物製劑先導工廠」爲研究對象，依國內外相關cGMP及生物安全第三等級寶驗室法規規定，將空間環境及硬體設備之需求，整合爲動線（含空間）、隔間、空調、電力、警報及監控、給排水及污水、儀器設備等七項指導性規範及設計要求；進而分析「人用疫苗製程空間」案例內之生物安全分區、清淨度區域、人流進出動線、器材（乾淨、污染）進出動線、製劑（培養緩衝液、產品）進出動線、廢棄物離開動線、壓力流向等七項目，以提供檢討與改進建議。本研究除闡述說明安全設計之觀念及方法外，並配合具相當經驗之專家訪談加上國內目前「生物製劑先導工廠」實務規劃案例，其研究成果將有助國內政府單位及醫療產業在面對大型傳染性疾病侵襲而來的同時，快速建立一符合生物安全高標準之「生物製劑先導工廠」，以提供防疫所需的生物製劑；且一旦爆發人傳人流感疫情時，也能在最短時間內，量產所需的抗毒藥物與疫苗以抑制疫情的擴散。

This study takes the highly dangerous ”Biological Pharmaceutical Pilot Factory” as the research object, and in accordance with domestic and foreign regulations on cGMP and Biosafety Level 3 Laboratory, space environment and hardware equipment are integrated into seven guiding regulations and design requirements that include moving paths (including spaces). compartment, air conditioning, electrical power, alarm and surveillance, water supply and sewage, and equipment; and further analyzed is the case study of ”human vaccine production space” that has seven categories of biosafety zoning, cleanliness areas, human flow moving paths, equipments (clean and contaminated) in-out moving paths, pharmaceutical agents (cultivation of buffer solution and products) moving paths, disposed wastes retreat paths, and pressure flow, to provide recommendations for reviews and improvement.This study elaborates the concept and methods of the safety design, and based on interviews with highly experienced experts as well as ease studies of domestic ”Biological Pharmaceutical Pilot Factory”, the results of this research can help the government and the medical industry, in the face of large-scale invasion of infectious diseases, rapidly establish a ”Biological Pharmaceutical Pilot Factory” of high biosafety standard, to provide the needed biological agents for disease prevention; and once a human transmitted influenza or epidemic breaks out, massive production of anti-virus drugs and vaccines can be undertaken in the shortest possible time to inhibit the spread of the epidemic.

1. 行政院衛生署(2004)《生物安全第三等級實驗室安全規範(第1. 0 版)》，台灣。Department of Health, Executive Yuan, Centers for Disease Control (2004) Safety Guidelines for Biosafety Level 3 Laboratory, Taiwan.
2. WHO (2004) Laboratory Biosafety Manual third edition, Geneva..
3. 張靜文， 于台珊(2003)《生物安全極種類、選用依據及操作安全介紹》，勞工安全衛生研究所，台灣。Zhang, Jing-Wen and Yu, Tai-Shan (2003) Types of biological safety cabinets, the choice of basis and safe introduction, Institute of Occupational Safety and Health, Taiwan.。
4. 吳百豐(2003)〈清淨度分級規劃與改善措施〉《cGMP 無菌作業區清淨度分級及環境監控作業研討說明會》 ，行政院衛生署，台灣。Wu, Bai-Fong (2003) Cleanliness grade program and improvement measures, The Conference on Cleanliness Classification and Eovironmental Monitoring Operations for cGMP Aseptic Work Area, Department of Health, Executive Yuan, Taiwan。
5. 鄭詠仁(2004)《生物安全櫃操作安全技術手冊》， 勞工安全衛生研究所，台灣。Zheng, Yong-Ren (2004) Biological security cabinet operational safety technical manual, Institute of Occupational Safety and Health, Taiwan.。
6. 行政院衛生署(2004)《藥物製造工廠設廠樣準》， 台灣。Department of Health, Executive Yuan (2004) Pharmaceutical Manufacturing Plant Establishment Standards, Taiwan。
7. 行政院衛生署(1999) 《藥品優良製造確效作業基準》台灣。Department of Health, Executive Yuan(1999) Current Good Manufacture Practice (cGMP) , Taiwan。
8. Center for Disease Control and Prevention, National Institute of Health(1999).Biosafety in Microbiological and Biomedical Laboratories(BMBL).USA:U.S. Govemment Printing Office.
9. NIH(1997).NIH Guidelines For Research Involving Recombinant DNA Molecules.USA:
10. William, Whyte(2000).Cleanroom Technology:Fundamentals of Design, Testing and Operation.USA:John Wiley & Sons, Ltd..
11. 喻文莉(2006)。台灣=Taiwan，台灣大學土木工程學研究所=Institute of Civil Engineering, National Taiwan University。